Why the world must aim to eliminate PEPFAR and end the HIV epidemic
But preserving PEPFAR shouldn't be seen as the end goal. Instead, global health officials should be working toward the day when the world no longer needs it.
That ambitious goal might sound far-fetched, given that an estimated 1.3 million people were newly infected with HIV in 2023 globally. But consider this: Last month, the Food and Drug Administration approved a drug called lenacapavir, a twice-yearly injectable treatment that clinical trials have shown is 100 percent effective at preventing HIV infection among young women and 96 percent effective among gay and bisexual men and transgender people.
The drug has the potential to be a groundbreaking improvement over the current standard for HIV prevention, oral PrEP (pre-exposure prophylaxis treatment). For all its promise, oral PrEP has confronted the difficult realities of human behaviour. Adhering to a daily medication regimen is challenging under any circumstances, but especially so in communities where HIV-related stigma is pervasive. Even in wealthier countries, gay men who take the medication have been disparaged. Oral PrEP also tends to be less effective in women, though studies differ on whether this is due to lower adherence and access barriers or biological differences in how the medication is absorbed in female anatomy.
Lenacapavir, manufactured by Gilead Sciences, could help address these challenges. It is discreet and can be administered privately in a clinical setting. It requires dosing only twice a year, and it is easier and less painful to administer than previous injectable drugs to prevent HIV.
In the United States, lenacapavir costs more than $28,000 per person per year before insurance. But Gilead has licensed six generic manufacturers to produce the drug at cost for 120 low- and middle-income countries. Together with the Global Fund, the company has pledged to distribute 2 million doses - still a drop in the bucket compared to what's needed for population-level protection, but a meaningful start.
Video Player is loading.
Play Video
Play
Unmute
Current Time
0:00
/
Duration
-:-
Loaded :
0%
Stream Type LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
0:00
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text Color White Black Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Transparent Semi-Transparent Opaque
Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps
Reset
restore all settings to the default values Done
Close Modal Dialog
End of dialog window.
Advertisement
Next
Stay
Close ✕
Ad loading
Of course, the drug is no silver bullet. Unfortunately none of the licensed generic manufacturers are based in sub-Saharan Africa, the region with the greatest need, and scaling up production could take years. So far, the U.S. is the only country to approve it, and regulatory timelines elsewhere are likely to lag.
Nevertheless, lenacapavir is exciting for what it represents: An innovation that can draw PEPFAR into a new era defined not by fighting HIV, but ending it. Advocates of the program should remember that it was designed as an emergency response to an uncontained pandemic; for it to become a permanent fixture of global health would constitute a failure of its mission.
Moreover, the program is far from perfect. Like many HIV prevention programs, it often sacrifices preventative care for treatment when budgets tighten. Those trade-offs stand in the way of HIV elimination. The program is also, regrettably, subject to the whims of U.S. politics. In February, Secretary of State Marco Rubio restricted HIV prevention aid so that only pregnant and breastfeeding women can receive it - as if to invite more AIDS epidemics.
The world has a long way to go until PEPFAR can safely be shuttered. After all, foundations and private companies cannot replace the program, which provides nearly 70 percent of global financing for HIV/AIDS response. But it's possible to imagine a future in which biomedical science and investments into a sustainable health infrastructure make the program obsolete. That's something the world should strive for. - The Washington Post
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
eNCA
11 minutes ago
- eNCA
US migrant raids spark boom for private detention providers
Donald Trump's promise to carry out the largest deportation operation in US history has appalled some Americans. But others are cashing in on the boom in demand for private detention centers. Migrants captured by Immigration and Customs Enforcement agents need to be temporarily housed in places like the facility being readied in California City, prior to deportation. "When you talk to the majority of residents here, they have a favorable perspective on it," said Marquette Hawkins, mayor of the hardscrabble settlement of 15,000 people, 160 kilometres north of Los Angeles. "They look at the economic impact, right?" California City is to be home to a sprawling detention center that will be operated by CoreCivic, one of the largest companies in the private detention sector. The company, which declined AFP requests for an interview, says the facility would generate around 500 jobs, and funnel $2 million in tax revenue to the city. "Many of our residents have already been hired out there to work in that facility," Hawkins told AFP. "Any revenue source that is going to assist the town in rebuilding itself, rebranding itself, is going to be seen as a plus," he said. - Boom - Trump's ramped-up immigration arrests, like those that provoked protests in Los Angeles, saw a record 60,000 people in detention in June, according to ICE figures. Those same figures show the vast majority have no conviction, despite the president's election campaign promises to go after hardened criminals. AFP/File | Patrick T. Fallon More than 80 percent of detainees are in facilities run by the private sector, according to the TRAC project at Syracuse University. And with Washington's directive to triple the number of daily arrests -- and $45 billion earmarked for new detention centers -- the sector is looking at an unprecedented boom. "Never in our 42-year company history have we had so much activity and demand for our services as we are seeing right now," Damon Hininger, executive director of CoreCivic, said in a May call with investors. When Trump took office in January, some 107 centers were operating. The number now hovers around 200. For Democratic politicians, this proliferation is intentional. "Private prison companies are profiting from human suffering, and Republicans are allowing them to get away with it," Congresswoman Norma Torres told reporters outside a detention center in the southern California city of Adelanto. At the start of the year, there were three people detained there; there are now hundreds, each one of them attracting a daily stipend of taxpayer cash for the operator. Torres was refused permission to visit the facility, run by the privately owned GEO Group, because she had not given seven days' notice, she said. "Denying members of Congress access to private detention facilities like Adelanto isn't just disrespectful, it is dangerous, it is illegal, and it is a desperate attempt to hide the abuse happening behind these walls," she said. "We've heard the horrifying stories of detainees being violently arrested, denied basic medical care, isolated for days, and left injured without treatment," she added. Kristen Hunsberger, a staff attorney at the Law Center for Immigrant Advocates, said one client complained of having to wait "six or seven hours to get clean water." It is "not sanitary and certainly not... in compliance with just basic human rights." Hunsberger, who spends hours on the road going from one center to another to locate her clients, says many have been denied access to legal counsel, a constitutional right in the United States. Both GEO and ICE have denied allegations of mistreatment at the detention centers. "Claims there is overcrowding or subprime conditions in ICE facilities are categorically FALSE," said Tricia McLaughlin, the assistant secretary at the Department of Homeland Security. "All detainees are provided with proper meals, medical treatment and have opportunities to communicate with their family members and lawyers." - 'Strategy' - But some relatives of detainees tell a different story. Alejandra Morales, an American citizen, said her undocumented husband was detained incommunicado for five days in Los Angeles before being transferred to Adelanto. In the Los Angeles facility, "they don't even let them brush their teeth, they don't let them bathe, nothing. They have them all sleeping on the floor, in a cell, all together," she said. Hunsberger said that for detainees and their relatives, the treatment appears to be deliberate. "They're starting to feel that this is a strategy to wear people down, to have them in these inhumane conditions, and then pressure them to sign something where they could then agree to being deported," she said.
The Citizen
9 hours ago
- The Citizen
Motsoaledi urges innovation to end TB
Minister of Health, Dr Aaron Motsoaledi, has stressed the urgent need for innovative solutions to combat tuberculosis (TB), a disease that has historically affected not just South Africa but also countries around the world. 'We are here because we believe that TB – a disease that has shaped the history and health of our country and indeed, the whole world – can be ended. Not through words alone, but through action, partnership, and innovation,' he said on Thursday. The Minister was delivering a keynote address at the country's TB Vaccine Preparedness Workshop held in Johannesburg. The workshop is aimed at advancing policy and decision-making for the introduction of TB vaccines. Addressing policymakers, scientists and community leaders, Motsoaledi stated that the upcoming phase will introduce preventative TB vaccination measures, which will also enhance the ongoing fight against HIV and Aids. For over a century, South Africa has relied on the Bacille Calmette-Guérin (BCG) vaccine to protect its children from TB, but the Minister pointed out that there has been no tool that can protect adolescents and adults. 'These are the very groups most at risk of getting sick and transmitting TB.' With several new TB vaccine candidates in the late stages of clinical trials, the most promising options are expected to be available in the next few years. This workshop positioned the country as one of the first that is ready to deliver a new generation of TB vaccines to the most vulnerable populations, including adolescents and adults. The Minister expressed confidence that the upcoming clinical trials would yield positive results, potentially leading to a new vaccine for older age groups within the next few years. TB is a leading cause of death from an infectious disease and a major contributor to ill-health in South Africa and globally. 'Imagine the day when we announce the availability of the vaccine for tuberculosis,' he said, likening it to 'the day of true freedom from slavery' for those suffering from the disease. Motsoaledi described the disease as a form of 'devastating slavery' that exacerbates poverty and leads to premature death. 'South Africa is not waiting for the world to act. We are preparing – intentionally, early and inclusively.' The Minister has used the first national gathering dedicated to the TB vaccine readiness platform to reiterate South Africa's commitment to lead by example in the global fight against TB and HIV. 'When South Africa wins against TB and HIV and Aids the world will win the war,' he said. He told the attendees that through his tenure as Health Minister, he consistently sought to elevate the profile of TB on a global scale. Motsoaledi recalled his 2018 address at the United Nations, where he rallied for world leaders to commit to addressing the TB crisis. 'While global attention has often turned to emerging health threats, South Africa has remained focused on the enduring challenge of TB,' he said. He also acknowledged the disease's severe impact on communities already struggling with HIV. 'Today's discussions remind us that vaccine introduction is not just about science – it is about health systems. It is about trust. It is about readiness.' He also used the platform to emphasise the importance of preparing the health sector for the rollout of the TB vaccine. The agenda for the workshop highlighted key thematic areas crucial for readiness, including generating evidence for policy and investment, strengthening delivery systems for TB vaccines, and ensuring manufacturing and supply chain readiness. 'Investment in human life means everything,' he said, stressing the need for robust financial backing to ensure effective vaccine deployment. The Minister took the time to urge stakeholders to foster community trust and strong advocacy to ensure widespread acceptance of the TB vaccine upon its introduction. 'We must walk the path with our people,' he said. –
TimesLIVE
11 hours ago
- TimesLIVE
The journey from detection to protection: inside South Africa's hepatitis testing gaps
Egypt showed the world what's possible. Their national hepatitis C programme screened more than 60-million people and treated more than four million — all within five years. This was the result of a public health campaign that brought public and private partners together to inspire a nationwide commitment to eliminating the silent killer. South Africa has the tools, the partnerships and the healthcare workforce to do the same. So why haven't we? Part of the answer lies in awareness. In a recent survey, most South Africans said they didn't know hepatitis was a serious disease. Many had never been offered a test. The virus doesn't always present symptoms early, so it slips beneath the surface — undiagnosed, untreated and unspoken. But another part of the answer lies in how we design our health priorities. Testing for hepatitis still isn't fully integrated into existing services. For example, we've done critical work to normalise HIV testing — it's part of antenatal visits, school programmes, even workplace health drives. Hepatitis should be just as visible. It should be part of every antenatal screening, every STI check-up, every blood drive. Testing for one virus shouldn't mean ignoring others. There's also a missed opportunity in our corporate and community health environments. The burden of hepatitis doesn't stop at the clinic door. Chronic liver disease affects productivity, health budgets and family stability. While specific cost data is limited in South Africa, international evidence is clear: investing in integrated testing and early diagnosis reduces healthcare costs and improves lives. The World Health Organisation has set a goal: eliminate hepatitis as a public health threat by 2030. To get there, South Africa must do three things: Normalise integrated testing for hepatitis B and C. Expand public education to match the scale of the risk. Mobilise partnerships between government, private sector, and civil society to scale up access. Hepatitis isn't rare. It isn't untreatable. And it isn't too late. But every day we wait, we lose lives that could have been saved with a test. Let's not let silence stand in the way of protection. Let's make this the decade where South Africa turns detection into action — and action into health. Everyone deserves to get tested.
